Key Highlights
- 26.39% of the float in Tango Therapeutics (NASDAQ:TNGX) is sold short with 12.5 days to cover, per published market data (October 16, 2026 intraday). Updated pancreatic cancer data are due at ESMO, October 23 to 27, 2026, seven days from October 16, own arithmetic.
- 29.36% of the float in Upstart (NASDAQ:UPST) is sold short with 6.2 days to cover. Third quarter earnings are reported for November 3, 2026, with consensus of USD 365.1 million of revenue and USD 83.2 million of adjusted EBITDA, per published coverage.
- 32.19% of the float in Intellia (NASDAQ:NTLA) is sold short, the highest of the four, with 9.5 days to cover. The FDA action date for lonvo-z is March 10, 2027, per the 8-K dated September 8, 2026, after Priority Review.
- 26.74% of the float in POET Technologies (NASDAQ:POET) is sold short with 3.2 days to cover. Engineering samples under the USD 50 million Lumilens purchase order are expected in late 2026, and the results date is not confirmed.
Tango Therapeutics (NASDAQ:TNGX)
The data event is seven days away, and one share in four is sold short. Tango Therapeutics (NASDAQ:TNGX) quoted USD 22.66 on October 16, 2026, down 0.20%, for a USD 3.82 billion market capitalisation, with no company-specific catalyst identified for the session. The June 8, 2026 release reported a 92% objective response rate (11 of 12 evaluable patients) for vopimetostat with daraxonrasib, with a 90% six-month progression-free survival rate. FINRA data show 44.5 million shares short, worth USD 1.01 billion at the quote (own arithmetic), equal to the USD 1.0 billion of cash at June 30. Days to cover of 12.5 implies average volume of 3.56 million shares (own arithmetic). What separates it from the other three: the nearest date and the longest exit queue. So what: strong data could force buying into thin supply. Small samples, partner dependence on Revolution Medicines drugs and Phase 3 cost are the short case. Piper Sandler cut its rating to Neutral on May 15, 2026.
Upstart (NASDAQ:UPST)
The test is funding, not demand. Upstart (NASDAQ:UPST) quoted USD 24.54 on October 16, 2026, down 0.85%, for a USD 2.39 billion market capitalisation. Preliminary third quarter originations of USD 4.1178 billion were 2.6% below the second quarter, leaving no cushion for a take rate shortfall. FINRA data for September 30 show 28.57 million shares short, worth USD 701 million at the quote (own arithmetic), at 6.23 days to cover. One customer accounted for 36% of second quarter revenue, and borrowings were USD 2,003.1 million at June 30, 2026. The company reaffirmed a full-year adjusted EBITDA target of USD 294 million, and first-half EBITDA of USD 117.4 million plus consensus for the two remaining quarters totals USD 294.5 million (own arithmetic). What separates it from the other three: it is the only one with a quarterly earnings event inside the next month. So what: a beat with firm funding commentary is the most direct covering trigger, and the average analyst target of USD 40.00 reflects disagreement. Short interest for the October 30 settlement is due November 10.
Intellia (NASDAQ:NTLA)
A short into an FDA date is a bet that approval is priced in. Intellia (NASDAQ:NTLA) quoted USD 11.38 on October 16, 2026, for a USD 1.59 billion market capitalisation, after an October 15 close of USD 11.34 at the bottom of its 50-day range. FINRA data show 46,681,609 shares short, worth USD 531 million at the quote (own arithmetic), and imply 14.1 days to cover on a 5.09 million share average volume. Cash of USD 628.4 million is 39.5% of market capitalisation (own arithmetic) and is a company estimate to fund operations into 2028, excluding lonvo-z revenue. Phase 3 results showed an 87% reduction in monthly attack rates against placebo. The short case sits in nex-z, where the highest liver enzyme elevations appeared in patients with one HLA allele. What separates it from the other three: the highest short percentage and the longest runway to its catalyst, 145 days to the FDA date (own arithmetic). So what: approval could also trigger an equity raise, which caps rallies. Third quarter results are estimated for November 5, 2026.
POET Technologies (NASDAQ:POET)
The setup has fuel and no clock. POET Technologies (NASDAQ:POET) quoted USD 5.89 on October 16, 2026, down 1.91% and 71.7% below the 52-week high of USD 20.81 (own arithmetic). Quarterly revenue was USD 569,925, so the USD 1.02 billion table market capitalisation is 447 times annualised sales (own arithmetic). Cash and short-term investments of USD 796.3 million at June 30 equal 78% of that value (own arithmetic). Wolfpack Research published a short report on April 14, 2026, and a class action followed on April 29. FINRA data show 18.3% of shares outstanding short, against 26.74% of float in the table. What separates it from the other three: the lowest days to cover, so a squeeze would be brief, and no confirmed date. The Lumilens agreement of May 14, 2026 covers an initial USD 50 million purchase order, with potential purchases above USD 500 million over five years. So what: engineering samples in late 2026 are the testable milestone, and the May offering of 19,047,620 units at USD 21 left warrants as overhang.
Where Things Stand
Tango Therapeutics (NASDAQ:TNGX) has the nearest dated catalyst, ESMO from October 23, 2026. Upstart (NASDAQ:UPST) follows on November 3, 18 days from October 16 (own arithmetic). Intellia (NASDAQ:NTLA) follows with estimated earnings on November 5 and the FDA date on March 10, 2027. POET Technologies (NASDAQ:POET) has only an unconfirmed late 2026 milestone. By short interest, NTLA leads at 32.19%, then UPST at 29.36%, POET at 26.74% and TNGX at 26.39%, so POET ranks above TNGX on percentage but last on days to cover. A catalyst makes a squeeze possible and does not make it probable.





_11_13_2026_20_30_45_840725.jpg)
Please wait processing your request...